Angela Di Paola, PhD
Postdoctoral AssociateAbout
Research
Publications
2025
A qualitative examination of barriers and facilitators to HIV prevention and treatment for people involved with the criminal justice system
Villaire S, Sease T, Pankow J, Bennett A, Pulitzer Z, Hansen L, Frank C, Di Paola A, Lehman W, Sanchez M, McQuaid A, Schultheis A, Stein B, Springer S, Nijhawan A, Knight K. A qualitative examination of barriers and facilitators to HIV prevention and treatment for people involved with the criminal justice system. Health & Justice 2025, 13: 37. PMID: 40478391, PMCID: PMC12143099, DOI: 10.1186/s40352-025-00344-6.Peer-Reviewed Original ResearchFocus groupsContext themesCommunity healthcare providersCriminal justice systemTrained qualitative researchersImplementation science frameworkMethodsSix focus groupsAudio-recorded interviewsNIDA-funded projectFocus group transcriptsDeductive coding strategiesDevelopment of interventionsFocus group processExamination of barriersSubstance use disorder preventionFocus group dataIntra-agency communicationPatient navigationPeer navigatorsCommunity serviceJustice systemIntervention implementationHIV careGroup transcriptsHealthcare providersInitiating Injectable Buprenorphine in People Hospitalized With Infections
Seval N, Roth P, Frank C, Di Paola A, Litwin A, Vander Wyk B, Neirinckx V, Schlossberg E, Lawson P, Strong M, Schade M, Nunez J, Levin F, Brady K, Nunes E, Springer S. Initiating Injectable Buprenorphine in People Hospitalized With Infections. JAMA Network Open 2025, 8: e2513000. PMID: 40445619, PMCID: PMC12125644, DOI: 10.1001/jamanetworkopen.2025.13000.Peer-Reviewed Original ResearchConceptsLong-acting buprenorphineOpioid use disorderReceipt of MOUDRandomized clinical trialsTAU armIntent-to-treat outcomesClinical trialsModerate to severe opioid use disorderSevere opioid use disorderProportion of patientsMultisite randomized clinical trialHospital settingStatistically significant differenceNursing case management servicesInfectious diseasesTAU groupMedian ageMedication management interventionCase management servicesInjectable buprenorphineHospitalization periodPrimary outcomeBaseline valuesInitiate MOUDMOUD receiptPilot Findings From the First Legalized Mobile Retail Pharmacy Clinic in the United States for Infectious Disease Treatment and Prevention Tailored to Reach People Who Use Drugs
Tarfa A, Di Paola A, Frank C, Schultheis A, Brooks R, Shenoi S, Springer S. Pilot Findings From the First Legalized Mobile Retail Pharmacy Clinic in the United States for Infectious Disease Treatment and Prevention Tailored to Reach People Who Use Drugs. Open Forum Infectious Diseases 2025, 12: ofaf200. PMID: 40276721, PMCID: PMC12019630, DOI: 10.1093/ofid/ofaf200.Peer-Reviewed Original ResearchHuman immunodeficiency virusHepatitis C virusOpioid use disorderAntiretroviral therapyViral loadHepatitis C virus viral loadTested HIVHuman immunodeficiency virus diagnosisSexually transmitted infection testingHepatitis C virus antibodyModerate to severe opioid use disorderDirect-acting antiviralsSevere opioid use disorderHIV antiretroviral therapyInfectious disease treatmentHCV VLImmunodeficiency virusPreexposure prophylaxisCommunity health workersPilot findingsC virusPostexposure prophylaxisHCV testingPositive testSubstance use disordersP-511. Missed Opportunities for Pre-Exposure Prophylaxis Initiation in Hospitalized Persons with Opioid Use Disorder and Infectious Diseases
Parchinski K, Neirinckx V, Di Paola A, Ghantous T, Tarfa A, Shenoi S, Strong M, Roth P, Levin F, Brady K, Nunes E, Frank C, Litwin A, Springer S. P-511. Missed Opportunities for Pre-Exposure Prophylaxis Initiation in Hospitalized Persons with Opioid Use Disorder and Infectious Diseases. Open Forum Infectious Diseases 2025, 12: ofae631.710. PMCID: PMC11779160, DOI: 10.1093/ofid/ofae631.710.Peer-Reviewed Original ResearchOpioid use disorderPerceived risk of HIVRisk of HIVHIV infectionLow risk of HIV infectionRisk factorsModerate to severe opioid use disorderRisk of HIV infectionLong-acting injectable buprenorphinePrevent HIV acquisitionCo-occurring infectionsSevere opioid use disorderPre-Exposure Prophylaxis InitiationHIV risk factorsCondomless sexual intercourseRetrospective data analysisHIV prevention carePre-exposure prophylaxisHIV risk behaviorsIncrease PrEP uptakeAdmission to hospitalAntiretroviral therapyHIV acquisitionProphylaxis initiationHIV testingP-1402. Will You Receive HIV and HCV Testing from a Mobile Pharmacy? Pre-implementation Needs Assessment and Pilot Findings from the United States First Legal Retail Mobile Pharmacy
Tarfa A, Frank C, Brooks R, Schultheis A, Di Paola A, Shenoi S, Springer S. P-1402. Will You Receive HIV and HCV Testing from a Mobile Pharmacy? Pre-implementation Needs Assessment and Pilot Findings from the United States First Legal Retail Mobile Pharmacy. Open Forum Infectious Diseases 2025, 12: ofae631.1577. PMCID: PMC11779293, DOI: 10.1093/ofid/ofae631.1577.Peer-Reviewed Original ResearchCommunity health workersMobile pharmaciesOpioid use disorderAlcohol use disorderHIV testingPre-implementationSubstance use disordersNeeds assessmentNavigating health care systemsCare delivery modelsHCV testingHealth care systemProviding health servicesRisk of HIVUse disorderMD-MPHAccessing CareHealth workersService useCharacterize barriersHealth screeningHealth servicesPharmacy servicesHealth careCare system
2024
Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases
Parchinski K, Neirinckx V, Frank C, Di Paola A, Tarfa A, Shenoi S, Vander WyK B, Roth P, Ghantous T, Wegman M, Strong M, Levin F, Brady K, Nunes E, Litwin A, Springer S. Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases. Open Forum Infectious Diseases 2024, 11: ofae366. PMID: 39022389, PMCID: PMC11252843, DOI: 10.1093/ofid/ofae366.Peer-Reviewed Original Research
2023
Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians
Di Paola A, Farabee D, Springer S. Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians. Psychiatric Research And Clinical Practice 2023, 5: 78-83. PMID: 37711754, PMCID: PMC10499189, DOI: 10.1176/appi.prcp.20230022.Peer-Reviewed Original ResearchStimulant use disorderUse disordersSevere opioid use disorderMini International Neuropsychiatric InterviewDiagnostic assessmentOpioid use disorderDisorder assessmentInternational Neuropsychiatric InterviewDSM-IV criteriaHarm reduction interventionsNon-clinical staffTraditional diagnostic assessmentInternal consistencyDSM-5 versionValid measureOpioid dependenceOpioid misuseImmediate treatmentNeuropsychiatric InterviewOpioid epidemicDisorder modulesOverdose deathsReduction interventionsNon cliniciansRapid diagnosisCorrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]
Lier A, Seval N, Vander Wyk B, Di Paola A, Springer S. Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]. Journal Of Substance Use And Addiction Treatment 2023, 150: 209074. PMID: 37271717, DOI: 10.1016/j.josat.2023.209074.Peer-Reviewed Original ResearchThe relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
Parchinski K, Di Paola A, Wilson A, Springer S. The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV. Drug And Alcohol Dependence Reports 2023, 7: 100159. PMID: 37159815, PMCID: PMC10163604, DOI: 10.1016/j.dadr.2023.100159.Peer-Reviewed Original ResearchOpioid use disorderExtended-release naltrexoneXR-NTXUse disordersKaplan-Meier survival analysisHIV viral suppressionMajor depressive disorderPublic health priorityOpioid cravingViral suppressionOpioid useHIV outcomesLife scoresRetrospective studyStudy baselineDepressive disorderOdds ratioDecrease recurrenceHealth prioritySurvival analysisPWHLifetime incarcerationStudy periodMean timeDisorders
2022
Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder
Lier A, Vander Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022, 9: ofac624. PMID: 36467300, PMCID: PMC9709708, DOI: 10.1093/ofid/ofac624.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusHCV treatment ratesHIV serostatusUse disordersHepatitis C virus (HCV) care cascadeHCV viral load testingTreatment ratesHCV treatment uptakeProspective cohort studyInjection drug useViral load testingGreater reductionDrug use frequencyHCV testingCare cascadeHCV antibodiesHIV screeningCohort studyHIV statusTreatment uptakeEntire cohortMedication treatmentC virusSerostatus